Harrow, Inc. (NASDAQ:HROW) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Harrow, Inc. has received an average rating of "Buy" from eight ratings firms, with seven analysts recommending a buy and one giving a strong buy rating, along with an average target price of $64.67.
• The company reported $0.24 earnings per share for the latest quarter, significantly exceeding the consensus estimate of $0.01, despite having a revenue of $63.74 million which was slightly below expectations.
• Institutional investors hold 72.76% of Harrow's stock, with notable increases in holdings from several firms, including a substantial 4,035.5% increase by Voya Investment Management LLC.

Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) have been given an average rating of "Buy" by the eight ratings firms that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $64.6667.

A number of equities research analysts have commented on HROW shares. HC Wainwright raised their target price on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Zacks Research upgraded Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Cantor Fitzgerald started coverage on Harrow in a research report on Friday, July 11th. They issued an "overweight" rating and a $76.00 price objective on the stock. BTIG Research upped their price objective on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Finally, William Blair started coverage on Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock.

Harrow Trading Down 4.5%

HROW opened at $37.36 on Tuesday. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -149.44 and a beta of 0.41. Harrow has a 52 week low of $20.85 and a 52 week high of $59.23. The business's 50 day moving average is $34.05 and its two-hundred day moving average is $29.18. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The company had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS. On average, research analysts predict that Harrow will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently bought and sold shares of the stock. Braidwell LP grew its holdings in Harrow by 5.5% in the first quarter. Braidwell LP now owns 956,839 shares of the company's stock valued at $25,452,000 after purchasing an additional 49,800 shares during the period. Geode Capital Management LLC increased its stake in Harrow by 4.7% during the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company's stock worth $24,765,000 after acquiring an additional 36,724 shares during the last quarter. D. E. Shaw & Co. Inc. increased its stake in Harrow by 6.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock worth $22,301,000 after acquiring an additional 41,896 shares during the last quarter. Marshall Wace LLP increased its stake in Harrow by 31.5% during the second quarter. Marshall Wace LLP now owns 564,876 shares of the company's stock worth $17,251,000 after acquiring an additional 135,202 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in Harrow by 4,035.5% during the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock worth $10,147,000 after acquiring an additional 372,237 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.